@EyeNewsMag Great overview. We reviewed all trials in detail (with aggregate results) here - Cochrane: https://t.co/3yFdMWpYoL
RT @nik_tzoumas: @dmastellos @TheLancet Thanks for sharing Dimitri, glad to see this published so scientific discussion can continue. We re…
RT @nik_tzoumas: @dmastellos @TheLancet Thanks for sharing Dimitri, glad to see this published so scientific discussion can continue. We re…
@dmastellos @TheLancet Thanks for sharing Dimitri, glad to see this published so scientific discussion can continue. We recently reviewed their Phase 2 methods & results, as well as the competing pegcetacoplan data, which otherwise remains unpublished:
@eyewiki Please cite the Cochrane review & meta-analysis! Phase 2 and 3 results of ALL complement inhibitors for AMD reported so far (efficacy, safety, bias, unpublished results) https://t.co/fwVip7fVWE https://t.co/Tb1AJj68X4
@DrewCareyMD Agree it's unfortunate but not practical for Phase 3 to reach sample sizes necessary to evaluate rare side-effects. No concerns re vasculitis previously: https://t.co/3yFdMWpYoL
@RetSpecMag @BioPharmaDive We recently explored the probable endophthalmitis risk of complement inhibitors for AMD in great detail: "complement inhibitors ... probably associated with a small risk of endophthalmitis, which may be higher than that of other
@RetinaToday @ApellisPharma @eyewireplus We recently explored the probable endophthalmitis risk of complement inhibitors for AMD in great detail: "complement inhibitors ... probably associated with a small risk of endophthalmitis, which may be higher than
@RetSpecMag @BioPharmaDive We explored the possible endophthalmitis risk of complement inhibitors for AMD in great detail here: "complement inhibitors ... possibly associated with a small risk of endophthalmitis, which may be higher than that of other int
RT @CochraneEyes: What are the benefits and risks of medicines that block complement to treat #AMD? Complement inhibitor for #AMD (age-rel…
RT @CochraneEyes: What are the benefits and risks of medicines that block complement to treat #AMD? Complement inhibitor for #AMD (age-rel…
RT @CochraneEyes: What are the benefits and risks of medicines that block complement to treat #AMD? Complement inhibitor for #AMD (age-rel…
RT @CochraneEyes: What are the benefits and risks of medicines that block complement to treat #AMD? Complement inhibitor for #AMD (age-rel…
RT @CochraneEyes: What are the benefits and risks of medicines that block complement to treat #AMD? Complement inhibitor for #AMD (age-rel…
What are the benefits and risks of medicines that block complement to treat #AMD? Complement inhibitor for #AMD (age-related macular degeneration) https://t.co/zGtoNadIOP https://t.co/bSK1m93bNu
RT @nik_tzoumas: Delighted to share the first-ever systematic review & meta-analysis of complement inhibitors for macular degeneration! Tha…
$CLSD $BCRX notice BCRX has "AMD" listed on a chart as a complement drug option. + new NCBI "IVT administration of complement inhibitors is probably associated with a small risk of endophthalmitis, which may be higher than that of other IVT therapies."
RT @nik_tzoumas: Delighted to share the first-ever systematic review & meta-analysis of complement inhibitors for macular degeneration! Tha…
RT @nik_tzoumas: Delighted to share the first-ever systematic review & meta-analysis of complement inhibitors for macular degeneration! Tha…
RT @nik_tzoumas: Delighted to share the first-ever systematic review & meta-analysis of complement inhibitors for macular degeneration! Tha…
RT @nik_tzoumas: Delighted to share the first-ever systematic review & meta-analysis of complement inhibitors for macular degeneration! Tha…
RT @nik_tzoumas: Delighted to share the first-ever systematic review & meta-analysis of complement inhibitors for macular degeneration! Tha…
Delighted to share the first-ever systematic review & meta-analysis of complement inhibitors for macular degeneration! Thanks to the unwavering committment of our exceptional authors, reviewers, and editors at @CochraneEyes over 3+ years. More to follo